Results 251 to 260 of about 6,047,039 (310)
Revealing the gap: fractional exhaled nitric oxide and clinical responsiveness to biological therapy in severe asthma - a retrospective study. [PDF]
ERJ Open ResManiscalco M +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinics in Plastic Surgery, 2000
Biologic therapy has evolved as a fourth treatment option for patients with melanoma and other malignancies. Interrelated advances in molecular diagnostics and gene therapy techniques will further accelerate therapeutic advances in this new arena. A variety of biologic therapeutic options available to the patient with high risk melanoma are reviewed.
H, Edington, S, Agarwala, J M, Kirkwood
openaire +2 more sources
Biologic therapy has evolved as a fourth treatment option for patients with melanoma and other malignancies. Interrelated advances in molecular diagnostics and gene therapy techniques will further accelerate therapeutic advances in this new arena. A variety of biologic therapeutic options available to the patient with high risk melanoma are reviewed.
H, Edington, S, Agarwala, J M, Kirkwood
openaire +2 more sources
Biological therapies for psoriasis
Expert Opinion on Biological Therapy, 2013Biological therapies have revolutionized moderate-to-severe psoriasis treatment. Increased understanding of disease pathogenesis has yielded multiple therapeutic targets involving the IL-23/Th17 pathway, while current therapies continue to be monitored for long-term efficacy and safety.This review details current understanding of psoriasis ...
Bobbak, Mansouri +2 more
openaire +2 more sources
Economics of biological therapies
BMJ, 2009Demand for biological drugs is putting pressure on health budgets.
Christopher J, Kelly, Fraz A, Mir
openaire +2 more sources
Current Opinion in Pulmonary Medicine, 2010
The use of immunomodulators in asthma has been well established with omalizumab. Evidence is accumulating for other biologic agents. The following article presents an overview of current biologic therapies employed and under investigation in the treatment of asthma.Anti-immunoglobulin E and anti-interleukin-5 are best supported by current evidence ...
David, Gruenberg, William, Busse
openaire +2 more sources
The use of immunomodulators in asthma has been well established with omalizumab. Evidence is accumulating for other biologic agents. The following article presents an overview of current biologic therapies employed and under investigation in the treatment of asthma.Anti-immunoglobulin E and anti-interleukin-5 are best supported by current evidence ...
David, Gruenberg, William, Busse
openaire +2 more sources
Psoriasis induced by biological therapy
Reumatología Clínica (English Edition), 2021To describe a multicentre case series of new onset or worsening of psoriasis in patients treated with biological drugs.Descriptive study. We reviewed the clinical history of patients with chronic inflammatory disease (CID) treated with biological drugs, who developed new onset or worsening of psoriasis during the follow-up period.Twenty-six cases of ...
Montolio Chiva L +5 more
openaire +4 more sources
Biologic therapies in the vasculitides
Current Opinion in Rheumatology, 2003Monoclonal antibody and recombinant DNA technologies have led to the development of biologic therapies capable of directly targeting selected components of the immune response. With the steady expansion of knowledge regarding the mechanisms of vascular inflammation, the safety and efficacy of biologic agents in the vasculitic diseases are being ...
Carol A, Langford, Michael C, Sneller
openaire +2 more sources
Inflammatory Bowel Diseases, 2007
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources